scPharmaceuticals Inc. (SCPH)

US — Healthcare Sector
Peers: CRNX  DMAC  FENC  IKT  MCRB  MIST  ONCY  PHAT  SRRK  VRCA 

Automate Your Wheel Strategy on SCPH

With Tiblio's Option Bot, you can configure your own wheel strategy including SCPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SCPH
  • Rev/Share 0.9302
  • Book/Share -0.3968
  • PB -14.0877
  • Debt/Equity -2.4605
  • CurrentRatio 3.8536
  • ROIC -1.1073

 

  • MktCap 297937497.0
  • FreeCF/Share -1.2264
  • PFCF -4.5224
  • PE -3.2742
  • Debt/Assets 0.6535
  • DivYield 0
  • ROE -20.8611

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
SCPH
Published: August 25, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceuticals shareholders. Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in c.

Read More
image for news SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
SCPH
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John Mohr - Senior Vice President of Clinical Development & Medical Affairs John H. Tucker - President, CEO, Principal Executive Officer & Director Rachael Nokes - Chief Financial Officer Steve C.

Read More
image for news scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
SCPH
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Read More
image for news scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
SCPH
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Neutral

Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and cut down on hospital readmissions. Q1 seasonality is in the rearview mirror, with multiple tailwinds, including Medicare redesign and label expansion, to fuel growth going forward.

Read More
image for news scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
SCPH
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call.

Read More
image for news scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
SCPH
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
SCPH
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences:

Read More
image for news scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

About scPharmaceuticals Inc. (SCPH)

  • IPO Date 2017-11-17
  • Website https://www.scpharmaceuticals.com
  • Industry Biotechnology
  • CEO John H. Tucker
  • Employees 162

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.